At a glance
ClinicalIndex Comparison RecordN/ACompleted· 1,315 enrolled
Drug / intervention
Pradaxa®drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Patients Assessment of Satisfaction for Stroke Prevention in Atrial Fibrillation Impact of Conventional Oral Anticoagulant (OAC) Compared With Novel Oral Anticoagulant (NOAC)
In Brief
An observational study evaluating Pradaxa® for Atrial Fibrillation. Completed, enrolled 1,315 participants across 24 sites.
Detailed Summary
To describe the treatment perception from patients with non-valvular atrial fibrillation (NVAF) receiving Pradaxa® or VKA for stroke prevention by using the self-estimation questionnaire of PACT-Q during a 6-month study period.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAtrial Fibrillation
CountriesTaiwan
Collaborators--
Timeline
N/ACompletedFinished
201820192020202120222023202420252026
First PostedJun 2017
Enrollment StartJun 2017
Primary CompletionJun 2018
Study CompletionJan 2019
TodayJul 2026
First PostedJun 14, 2017
Enrollment StartJun 20, 2017
Primary CompletionJun 30, 2018
Study CompletionJan 11, 2019
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 9.0 years ago
Interventions
Pradaxa®drug
Dabigatran etexilate